EP Vantage
EP Vantage
Stop FollowingEP Vantage
View as an RSS Feed
View EP Vantage's Articles BY TICKER:
ABII,
ABT,
AFFY,
ALIM,
ALIOF.PK,
ALNY,
ALTH,
ALXN,
AMGN,
ARIA,
ARQL,
ASTM,
AZN,
BAX,
BCRX,
BMTI,
BMY,
BSNRF.PK,
BSX,
CADX,
CBST,
CELG,
CEPH,
CHTP,
CORT,
COV,
CYPB,
CYTK,
DDSS,
DEPO,
DMYDF.PK,
DNDN,
ECYT,
ESALY.PK,
EW,
FOLD,
FRX,
GE,
GILD,
GSK,
GTXI,
HALO,
HEB,
IMGN,
INHX,
ISPH,
ISTA,
ITMN,
JAZZ,
JNJ,
KG,
LLY,
LMNX,
MDCO,
MDT,
MDVN,
MEDX,
MKGAF.PK,
MNKD,
MYGN,
NAVB,
NEUSF.PK,
NVS,
NYMX,
OMER,
ONXX,
OPOSF.PK,
PARD.PK,
PCYC,
PFE,
PPHM,
RHHBY.OB,
RIGL,
SCR,
SNN,
SNY,
STJ,
SVNT,
SXMDF.PK,
TEVA,
THRX,
TMO,
UCBJY.PK,
UTHR,
VPHM,
VRX,
VVUS,
WILLF.PK,
WMGI,
YMI
- ViroPharma Finally Able to Look Forward
- New Diabetes Drug Could Give Januvia Stiff Competition
- Once Again, Savient Disappoints Investors
- Inovio Shares Surge on News of Experimental Flu Vaccine Approach
- United Therapeutics: Gold Star Performance as Second FDA Approval Confirmed
- Lundbeck's Late Stage Pipeline Keeps Looking Thinner
-
Third Time's the Charm for Talecris IPO?
on Fri, Jul 31, 2009 • 1 Comment
- Human Genome Sciences Raises $310m on Huge Share Price
- King Pharma: FDA Headaches Continue
- BioMS Misses Out on Happily Ever After
- Amgen Partners with Glaxo to Distribute Prize Pipeline Product
- Sanofi's Move on Shantha Biotechnics Could Reignite Interest in Crucell
- Bristol-Myers Gets Its Antibody Deal at Last
- Elan's Tysabri Option with J&J Could Shift Balance of Power at Biogen Idec
- Labopharm: News Could Have Been Worse
- Lilly and Daiichi Finally Receive Effient Approval
- Pfizer Might Achieve Goal of Becoming Number 3 in Oncology, But Needs Heftier Sales
- J&J Comes Riding to Elan's Rescue
- Generic Players Continue to Impress in H1
- Cell Genesys: BioSante Sees Something Other than Cash
- Smaller Pharma Wins the 'Most Valuable' Race
- Biotech Set to Dominate Drug Industry Growth
- Genentech Seals Roche's Dominance of Oncology Market
- Gilead Follows Its Heart, Sweeps CV Away for $1.4B
- Will Johnson & Johnson Disrupt SchMerck?
- New Wave of Pharma Mergers with Merck - Schering-Plough Deal
- Genentech's Bullish Forecasts Are Not in Line with Wall Street
- Failure to Launch for Last Year's Big Pharma and Biotech Hopes
- La Jolla Drug Failure Leaves Few Options
- Will 2009 Be a Year for Pharma Currency Speculators?
- Pfizer-Wyeth Merger Looks Unwise
- Ustekinumab PDUFA Could Kick Start Medarex Revival
